

 **Cancer R&D 2024**
Nov 18-20, 2024 | Boston, MA

PROGRAM

9th International Conference on

CANCER RESEARCH & DRUG DEVELOPMENT

 November 18-20, 2024 | Boston, MA

 Boston Marriott Newton Hotel
2345 Commonwealth Avenue
Newton, MA

EXHIBITORS

 **Asfa Cytology**

AcroCyte

Exhibitors

Alfa Cytology



Alfa Cytology, based in New York, USA, is a research solutions provider, focused on cancer therapeutic development and preclinical studies. Its dedicated team of experienced scientists, bioinformatics experts, and professional oncologists collaborates to deliver customized solutions tailored to each client's specific needs. From the complex phases of target discovery to IND application, Alfa Cytology offers a seamless experience. Operating on a business model centered around fee-for-service, Alfa Cytology also provides platform license-out options. The one-stop drug discovery services and the diverse technology platforms will meet the various needs of the clients, ensuring innovative and effective research outcomes.


AcroCyte



AcroCyte Therapeutics Inc. is revolutionizing precision medicine through R3CE (Rapid, Reproducible, Rare Cell 3D Expansion)—the world's only technology that successfully cultures CTCs (Circulating Tumor Cells) from blood and creates personalized 3D cell cultures from any tissue specimen in a week. Our breakthrough eliminates the need for traditional cell lines and animal testing, empowering patients to access truly personalized treatments using their own cells. Through our Onco-REAL clinical detection service, we're transforming cancer care with precise, patient-specific solutions.


Floor Plan

Day 1




Floor Plan

Day 2



Floor Plan

Day 3



Join Zoom Meeting:

<https://zoom.us/j/97915782567?pwd=d8cU9Mf7QWcfPODObj7GS34wHrAdyW.1>

Meeting ID: 979 1578 2567

Passcode: 570626

08:00-08:45 **Registrations and Badge Pickup**

08:50-09:00 **Welcome and Inaugural Note**

Chair: **Olga V Razorenova**, University of California Irvine, CA

PLENARY SESSION I

09:00-09:45



Eric B Kmiec

Executive Director & CSO, Gene Editing
Institute, Christiana Care, DE

**CRISPR-directed Gene Editing for
the Treatment of Solid Tumors**

09:45-10:30



X Shirley Liu

Co-founder & CEO
GV20 Therapeutics, MA

**AI-driven Next-generation
Biotherapeutics**

10:30-10:50

COFFEE BREAK

PLENARY SESSION II

10:50-11:35



John Quackenbush

Harvard T.H. Chan School of Public Health
Boston, MA

**Why Networks Matter: Embracing
Biological Complexity**

11:35-12:20



Sangeeta N Bhatia

Koch Institute for Integrative Cancer Research
MIT, Howard Hughes Medical Institute, MA

**Improving Cancer Detection with
Nanotechnology**

12:20-13:05



Raghu Kalluri

The University of Texas MD Anderson
Cancer Center, TX

**New Biology and Therapy Options
for Pancreatic Cancer**

Exhibitor's Talk: 13:05-13:20

Yvonne Lee, Alfa Cytology, NY

Designing your Preclinical Cancer Modeling Mouse Studies

Chair: **Bi-Dar (Peter) Wang**, University of Maryland Eastern Shore School of Pharmacy, MD

PLENARY SESSION III


14:10-14:55



Andrea Califano
Columbia University
NY

Elucidation and Pharmacologic Targeting of Master Regulator Dependencies at the Single Cell Level

14:55-15:40



A Thomas Look
Dana-Farber Cancer Institute, Harvard
Medical School, MA

Combinations of Epigenetic Inhibitors to Drive Terminal Differentiation of Developmental Cancers

15:40-16:25



Eytan Ruppin
NCI, National Institutes of Health
MD

Next Generation Precision Oncology: From Omics to Slides

16:25-16:35

COFFEE BREAK

KEYNOTES

16:35-17:10



Haihui Lu
Novartis Institutes for Biomedical
Research, MA

Empowering T-cell Engagers with Novel Designs to Unleash Potent Activity on Tumors

17:10-17:45



Hui Shen
Van Andel Institute
MI

New Single Cell Technologies to Study the Trajectory of Ovarian Cancer Stem-like Cells

- CRD- P1** **Madiha Kanwal**, BIOCEV - Faculty of Science, Charles University, Czech Republic
ASPH Inhibition Reveals Differential Gene Expression Patterns in HPV-positive and HPV-negative Cell Lines
- CRD- P2** **Yiming Wang**, Chongqing University Cancer Hospital, Chongqing, China
CXCL12 Secreted by Cancer-associated Fibroblasts (CAFS) Activates the PI3K-Akt Pathway and induces Cisplatin Resistance in Lung Squamous Cell Carcinoma Cancer Cells
- CRD- P3** **Sravani K Ramisetty**, City of Hope National Medical Center, CA
Phenotypic Plasticity and Cellular Decision-making: Role of SLIT2 in Epithelial-To-Mesenchymal Transition
- CRD- P4** **Madeline Xu**, Indiana University School of Medicine, IN
The Synergy of SUMO1 Degradors and FOLFOX in Treatment of Colon Cancer
- CRD- P5** **Xinyi Shen**, Yale School of Public Health, CT
Precision Targeting of Ferroptosis in Colorectal Cancer: Sex and KRAS Mutation-driven Metabolic Vulnerabilities and Drug Repurposing
- CRD- P6** **Ana Martin-Vega**, UT Southwestern Medical Center, TX
ASCL1 Restrains ERK1/2 Activity to Promote Survival of a Subset of Neuroendocrine Lung Cancers
- CRD- P7** **Shivali Singh**, Gwinnett School of Mathematics, Science and Technology, GA
Identifying Novel Prognostic Biomarkers for Pancreatic Cancer
- CRD- P8** **Shashanka Shekhar Sarkar**, Indian Institute of Technology Ropar, India
Novel Small Molecule Inhibitor Targeting RNA Polymerase I Transcription: Potential Anti-tumor Agent

END OF DAY 1

PARALLEL SESSION-1

Meeting Room: Salon D

Join Zoom Meeting:

<https://zoom.us/j/97915782567?pwd=d8cU9Mf7QWcfPODObJ7GS34wHrAdyW.1>

Meeting ID: 979 1578 2567

Passcode: 570626

Chair: Olga V Razorenova, University of California Irvine, CA

KEYNOTES

Virtual 09:00-09:30

**Ying Xu**

Southern University of Science and Technology, China

Analyses of Cancer Omic Data Need a Fundamentally New Theoretical Framework

09:30-10:00

**Stanley P Leong**

University of California, San Francisco School of Medicine, CA

Cancer Metastasis Through the Lymphovascular System

10:00-10:30

**William Douglas Figg**

National Cancer Institute, National Institutes of Health, MD

Identify Novel, Rational Combinations of Targeted Therapies**Exhibitor's Talk:** 10:30-10:50**Ying Chih Chang**, AcroCyte Therapeutics, Inc., Taiwan | USA**Next Generation of Liquid Biopsy – Growing CTCs for Dynamic Prognostic Evaluation and Drug Surveillance**

10:50-11:10

COFFEE BREAK

CANCER METASTASIS

Chairs: Jing Huang, NCI, National Institutes of Health, MD

Arek Kulczyk, Rutgers University, NJ

11:10-11:30

Olga V Razorenova, University of California Irvine, CA**Metabolic Shift towards OxPhos Drives Triple Negative Breast Cancer Metastasis**

11:30-11:50

Jing Huang, NCI, National Institutes of Health, MD**Transcriptional and Epigenetic Dysregulation in Osteosarcoma**

11:50-12:10

William H Gmeiner, Wake Forest University, NC**Translational Studies with Fluoropyrimidine Polymers for Improved Treatment of GI-malignancies**

12:10-12:30

Georg F Weber, University of Cincinnati, OH**Novel Experimental Treatments of Cancer Metastasis**

12:30-12:50	Min Yu , University of Maryland School of Medicine, MD Single Cell Analysis of Human Brain Metastasis Reveals Conserved Populations and Niches	
12:50-13:50	LUNCH	
		Salon E
13:50-14:10	Bi-Dar (Peter) Wang , University of Maryland Eastern Shore School of Pharmacy, MD Reciprocal miR-99b-5p/MTOR Pairing as a Critical Regulator for AR Signaling and EMT-mediated Metastasis in Aggressive Prostate Cancer	
14:10-14:30	Mary L Alpaugh , Rowan University, NJ Characterization of a Poorly Understood Alternate Means of Metastasis	
14:30-14:50	Michele I Vitolo , University of Maryland School of Medicine, MD Targeting Tubulin Glutamylolation in Breast Cancer	
14:50-15:10	David Potter , University of Minnesota, MN Potential of Immune Checkpoint Blockade by Inhibition of Epoxyeicosatrienoic Acid Driven Tumor Respiration	
15:10-15:30	Sui Huang , Northwestern University, IL Metarrestin, a Perinucleolar Compartment Inhibitor, Effectively Suppresses Metastasis	
15:30-15:40	COFFEE BREAK	
15:40-16:00	Arek Kulczyk , Rutgers University, NJ Cryo-EM and AI Reveal the Molecular Basis Underlying Formation of the Laminin Matrix and Its Netrin-4-Dependent Disassembly with Implications for the Treatment of Metastatic Tumors	
16:00-16:20	Arrigo De Benedetti , LSU Health Shreveport, LA TLK1-MK5 Interaction as Druggable Target for Prostate Cancer metastasis	
16:20-16:40	Mei Shenglin , Harvard University, MA Cellular Architecture of Tumor Bone Metastasis	
16:40-17:00	Akdes Serin Harmanci , Baylor College of Medicine, TX Systems Biology Approaches for Target Discovery in Brain Tumors	
17:00-17:20	Aikaterini Kontrogianni-Konstantopoulos , University of Maryland School of Medicine, MD Targeting Giant Obscurin to Suppress Breast Cancer Metastasis	
17:20-17:40	Xinyi Shen , Yale School of Public Health, CT OncoSexome: A Database of Sex-based Differences in Oncologic Diseases	

PARALLEL SESSION-2

Meeting Room: Salon AB

Join Zoom Meeting:

<https://us06web.zoom.us/j/86111763972?pwd=5vodMxKT8FYsDQQCnOun5ksVTQAIot.1>

Meeting ID: 861 1176 3972

Passcode: 272408

CANCER TARGETED THERAPY

Chairs: **Ozgun Sahin**, Medical University of South Carolina, SC
Zohar Sachs, University of Minnesota, MN

11:10-11:30	Ana Gamero , Temple University, PA STAT2 Signaling as a Potential Therapeutic Target in Cancer	
11:30-11:50	Peiwen Chen , Cleveland Clinic, OH Dual Targeting Macrophages and Microglia is a Therapeutic Vulnerability in PTEN-deficient Glioblastoma	
11:50-12:10	Zohar Sachs , University of Minnesota, MN Mechanisms of Progression and the Aggressive Biology of TP53 Mutant AML	
12:10-12:30	Benjamin T Spike , The University of Utah, UT Targeting an Autocrine/Paracrine Vesicle Trafficking Mechanism for Therapy	
12:30-12:50	Tomoo Iwakuma , Children's Mercy Research Institute, MO Induction of p53 Synthetic Lethality for Cancer Therapy	
12:50-13:10	Anthony C Faber , VCU Massey Comprehensive Cancer Center, VA Pharmacological Targeting of SUMOylation Reverses BAF Complex Distribution in Synovial Sarcoma	
13:10-13:50	LUNCH	Salon E
13:50-14:10	Muhammad G Kibriya , The University of Chicago Biological Sciences, Chicago, IL Utility of Gene-environment Interaction in Terms of Somatic Variants and Transcriptomic Profile for Targeted Therapy in Precision Oncology	
14:10-14:30	Ozgun Sahin , Medical University of South Carolina, SC Targeting Chemoresistant Triple-negative Breast Cancer via a Highly Potent Bi-thiazole Inhibitor of LOX	
14:30-14:50	Jungsun Kim , OHSU Knight Cancer Institute, OR HBP1: A Double-edged Sword in Pancreatic Cancer Progression	
14:50-15:10	Xi Chen , MD Anderson Cancer Center, TX Stressing Out Therapy-resistant Cancers	
15:10-15:30	Stephan K Grant , Zentalis Pharmaceuticals, CA Azenosertib is a Selective WEE1 Kinase Inhibitor with Broad-spectrum Antitumor Activity in Preclinical Models and Encouraging Clinical Activity in Patients with Solid Tumors	
15:30-15:40	COFFEE BREAK	

CANCER IMMUNOTHERAPY

Chairs: **Geeta Upadhyay**, Uniformed Services University of the Health Sciences, MD
Fahri Saatcioglu, University of Oslo, Norway

KEYNOTE TALK

15:40-16:00



Geeta Upadhyay

Scientific Director, CBCP, John P. Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences, MD

Targeting LY6 Family Members for the Immunotherapy of Solid Cancer

- 16:00-16:20 **Ana Carrizosa Anderson**, Harvard Medical School and Brigham and Women's Hospital, Broad Institute, MA
Opioid Antagonism of Immune Checkpoint Blockade
- 16:20-16:40 **Fahri Saatcioglu**, University of Oslo, Norway
Interplay of ER Stress Signaling and the Tumor Microenvironment – Implications for Cancer Immunotherapy
- 16:40-17:00 **Yuxuan 'Phoenix' Miao**, The University of Chicago, IL
Targeting Stem Cell-specific Program to Prevent Cancer Relapse from Immunotherapy
- 17:00-17:20 **Zhibin Zhang**, MD Anderson Cancer Center, TX
Pyroptosis in Antitumor Immunity
- 17:20-17:40 **Robert Eil**, Oregon Health and Science University, OR
Organelle Ion Transport Integrates T Cell Metabolism and Function
- 17:40-18:00 **Guanqiao Li**, Tsinghua University, China
Decoding the Tumor Microenvironment: Cancer-associated Fibroblasts Activation and Neoadjuvant Therapy Outcomes in Lung Cancer

PARALLEL SESSION-3

Meeting Room: Salon FC

Join Zoom Meeting:

<https://us06web.zoom.us/j/85362204372?pwd=Av4RV0W60ajQhyW43htp3njlQbf9oQ.1>

Meeting ID: 853 6220 4372

Passcode: 080917

CANCER BIOLOGY & CELLULAR THERAPIES IN CANCER

Chair: Mumtaz V Rojiani, Penn State Cancer Institute, PA

- 11:10-11:30 **Jon Amund Kyte**, Oslo Metropolitan University, Norway
CAR T therapy for Treatment Resistant Solid Cancers
- 11:30-11:50 **Sima Lev**, Weizmann Institute of Science, Israel
Combination Therapies and Ferroptosis Vulnerability of Triple-negative Breast Cancer
- 11:50-12:10 **Cecil Han**, Georgetown University School of Medicine, Washington
Novel Role of Deubiquitinase USP13 in Lineage Plasticity of Lung Cancer
- 12:10-12:30 **Carlos Moreno**, Emory University, GA
Spatial Analysis of Aggressive Prostate Cancer Microenvironment at Single Cell Resolution
- 12:30-12:50 **Martin K Thomsen**, Aarhus University, Denmark
Unraveling the Role of ROCK1 in Driving the Diffuse Phenotype of NF1-Deficient Glioblastoma: Insights from Mouse Models and Single-cell RNA Sequencing
- 12:50-13:50 LUNCH Salon E
- Chairs: Norbert Volkmar**, DISCO Pharmaceuticals, Switzerland
Amy M Rojiani, Penn State College of Medicine, PA
- 13:50-14:10 **Kaifu Chen**, Harvard Medical School, MA
Mapping the Cancer RNA Modification Landscape by AI Analysis of Nanopore RNA Sequencing Signals
- 14:10-14:30 **Feng Yang**, Baylor College of Medicine, TX
Role of the COP1-GATA2 Axis in Prostate Cancer Suppression
- 14:30-14:50 **Bevin P Engelward**, Massachusetts Institute of Technology, MA
Role of DNA Repair in Modulating Susceptibility to Exposure-induced Carcinogenesis
- 14:50-15:10 **Wenwei Hu**, Rutgers Cancer Institute of New Jersey, NJ
The Alteration of Hepatic PPAR α and Lipid Metabolism in Cancer Cachexia
- 15:10-15:30 **Armita Bahrami**, Emory University School of Medicine, GA
Refining Classification in Sarcomas and Related Tumors Through Genomic Data
- 15:30-15:40 COFFEE BREAK
- 15:40-16:00 **Sunny Y Ruggeri**, University of Massachusetts Lowell, MA
Applying Data Mining Approaches to Model Oral-Endocrine-Therapy (OET) Adherence Behaviors among Women with Breast Cancer
- 16:00-16:20 **Yan Peng**, UT Southwestern Medical Center, TX
Breast Cancer Biomarkers 2024: HER2 Low and Ultra Low in Clinical Practice
- 16:20-16:40 **Jun Wang**, NYU Langone Health, NY
Flexible Dimer in Checkpoint Biology and Therapeutic Application
- 16:40-17:00 **Anelia Horvath**, The George Washington University, DC
ML-Enhanced Identification and Analysis of Expressed Mutations from scRNA-Seq Data

END OF DAY 2

Join Zoom Meeting:

<https://zoom.us/j/97915782567?pwd=d8cU9Mf7QWcfPODOBJ7GS34wHrAdyW.1>


Meeting ID: 979 1578 2567

Passcode: 570626

Chairs: **William H Gmeiner**, Wake Forest University, NC
Kaifu Chen, Harvard Medical School, MA

PLENARY TALKS

08:30-09:00

**Keith T Wilson**

Vanderbilt University
 Medical Center, TN

Molecular Targeting of Electrophilic Stress in Gastric and Colorectal Cancer: Hypusination, NRF2, and Scavenger Drugs

09:00-09:45

**Robert Weinberg**

Founding Member, Whitehead Institute for Biomedical Research, Director,
 MIT Ludwig Center for Molecular Oncology, Cambridge, MA

Non-genetic Mechanisms of Malignant Progression

NOVEL DRUG DEVELOPMENT AND CANCER RESISTANCE

09:45-10:05

John D Schuetz, St. Jude Children's Research Hospital, TN
Identification of a Novel Regulator of the Hedgehog pathway

10:05-10:25

Xiumei (Mae) Huang, Indiana University School of Medicine, IN
Targeting NQO1-Positive Cancer to Overcome Immune Checkpoint Resistance

10:25-10:35

COFFEE BREAK

10:35-10:55

Jean-Pierre Gillet, University of Namur, Belgium
Discovery of Two Novel Heterodimeric ABC Transporters in Melanoma: ABCB5 β /B6 and ABCB5 β /B9

10:55-11:15

Michael Farrar, University of Minnesota, MN
Leukemia Evades Immune Surveillance by Imposing a Type-1 Regulatory Program on Neoantigen-Specific CD4⁺ T-cells

11:15-11:35

Mumtaz V Rojiani, Penn State Cancer Institute, PA
TIMP-1 modulation Correlates with KRAS Dependency and EMT Induction in NSCLC

11:35-11:55

Lucas Horn, National Cancer Institute, MD
CXCR1/2 Inhibition Increases the Response of HPV-negative Head and Neck Squamous Cell Carcinoma Models to Docetaxel

11:55-12:15

Rebecca Hartman, Harvard University, MA
Novel Detection Methods in Melanoma Diagnosis

12:15-12:35

Etsuo A Susaki, Juntendo University Graduate School of Medicine, Japan
Tissue Clearing Technologies and Their Applications in Cancer Research and Drug Discovery


- 12:35-12:55 **Maryam Safari**, Columbia University Irving Medical Center, NY
Epigenetic Modulation in Pancreatic Cancer: Synergistic Inhibition of HDAC and eIF4A as a Targeted Therapeutic Approach
- 12:55-13:15 **Ozge Saatci**, Medical University of South Carolina, SC
Restoring Immunogenic Cell Death Overcomes Resistance to the Iconic Antibody-Drug Conjugate T-DM1 in HER2-positive Breast Cancer
- 13:15-13:35 **Annu Abhishek Choudhary**, Veer Narmad South Gujarat University, India
Metal Free, Visible light Mediated Synthesis of Tetracyclic Benzimidazole : Regioselective C-H Functionalization with *In-vitro* and Computational Study of Potent Compounds

13:35 LUNCH AND IN-PERSON DEPARTURES

Virtual

Eastern Standard Time Zone

PLENARY TALK



14:00-14:45

Douglas R Green

St. Jude Children's Research Hospital
TN

**Flatliners: Near Death Experiences
in Cancer Cells**

- 14:45-15:05 **Romi Gupta**, The University of Alabama at Birmingham, Alabama
ATAD2 is a Driver and a Therapeutic Target in Ovarian Cancer that Functions by Upregulating CENPE
- 15:05-15:25 **Uwe Rix**, Moffit Cancer Center, FL
Multi-node Targeting of Oncogenic Signaling Networks in Lung Cancer
- 15:25-15:45 **Pora Kim**, The University of Texas Health Science Center at Houston, TX
Systematic Bioinformatics Studies for the Development of the Targeted Therapeutics for Human Fusion Genes
- 15:45-16:05 **Hussein A Abbas**, University of Texas MD Anderson Cancer Center, TX
Dissecting Acute Myeloid Leukemia Immune Microenvironment to Understand Therapeutic Resistance
- 16:05-16:25 **Eugen Dhimolea**, Albert Einstein College of Medicine, NY
A Myc-suppressed Cell State Mediates Chemotherapy Persistence in Breast Cancer
- 16:25-16:45 **Yaqing Zhang**, University of Michigan, MI
CCR1 Drives Immunosuppressive Properties of Tumor Associated Macrophages in Pancreatic Cancer
- 16:45-17:05 **Yi Nan Gong**, University of Pittsburgh, PA
Death Experiencing Cancer Cell
- 17:05-17:25 **Shamim Mollah**, Washington University School of Medicine, MO
Deciphering Epigenetic Regulatory Mechanisms of Ifn γ -Induced Epithelial to Mesenchymal Transition in Human Breast Cells using Systems Approach
- 17:25-17:45 **Hilary Magruder Gaudet**, Wheaton College, MA
The Requirement of Septin-2 in Events Associated with Epithelial Ovarian Cancer Progression
- 17:45-18:05 **Frederick H Silver**, Rutgers, The State University of New Jersey, NJ
Noninvasive Detection of Cancerous Skin Melanomas using Vibrational Optical Coherence Tomography
- 18:05-18:25 **John Paul Shen**, University of Texas MD Anderson Cancer Center, TX
50,000 Patients and 2.4 Billion Single Cell Transcript Measurements: How Can Big Data Help Us Find Effective Treatments for Our Patients with Colorectal Cancer

See you again at
Cancer R&D 2025
November, Boston, USA

Organized by



UNITED Scientific
Group
A non-profit organization

USG United Scientific Group
(A non-profit organization)

#8105, Suite 112, Rasor Blvd, PLANO, TX 75024

Tel: +1 469-854-2280/81

Email: kkalagara@uniscigroup.net Web: <https://cancer.unitedscientificgroup.org/>